Press Releases

TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

TNF Pharmaceuticals Announces Closing of $7 Million Private Placement

TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025